期刊文献+

A defect in the activities of △~6 and △~5 desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease 被引量:2

A defect in the activities of △~6 and △~5 desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease
在线阅读 下载PDF
导出
摘要 Non-alcoholic fatty liver disease (NAFLD) is a low-grade systemic inflammatory condition, since liver and adipose tissue tumor necrosis factor-α (TNF-α) and TNF receptor 1 transcripts and serum TNF-α levels are increased and IL-6-/-mice are less prone to NAFLD. Fatty liver damage caused by high-fat diets is associated with the generation of pro-inflammatory prostaglandin E2 (PGE2). A decrease in the levels of arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and the usefulness of EPA and DHA both in the prevention and management of NAFLD has been reported. AA, EPA and DHA and their anti-inflammatory products lipoxins (LXs), resolvins and protectins suppress IL-6 and TNF-α and PGE2 production. These results suggest that the activities of △6 and △5 desaturases are reduced in NAFLD and hence, the dietary essential fatty acids, linoleic acid (LA) and α-linolenic acid (ALA) are not metabolized to their long-chain products AA, EPA and DHA, the precursors of anti-inflammatory molecules, LXs, resolvins and protectins that could prevent NAFLD. This suggests that an imbalance between proand anti-inflammatory bioactive lipids contribute to NAFLD. Hence, it is proposed that plasma and tissue levels of AA, EPA, DHA and LXs, resolvins and protectins could be used as predictors and prognostic biomarkers of NAFLD. It is suggested that the synthesis and use of more stable analogues of LXs, resolvins and protectins need to be explored in the prevention and management of NAFLD. Non-alcoholic fatty liver disease (NAFLD) is a low-grade systemic inflammatory condition, since liver and adipose tissue tumor necrosis factor-α (TNF-α) and TNF receptor 1 transcripts and serum TNF-α levels are increased and IL-6-/-mice are less prone to NAFLD. Fatty liver damage caused by high-fat diets is associated with the generation of pro-inflammatory prostaglandin E2 (PGE2). A decrease in the levels of arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and the usefulness of EPA and DHA both in the prevention and management of NAFLD has been reported. AA, EPA and DHA and their anti-inflammatory products lipoxins (LXs), resolvins and protectins suppress IL-6 and TNF-α and PGE2 production. These results suggest that the activities of △6 and △5 desaturases are reduced in NAFLD and hence, the dietary essential fatty acids, linoleic acid (LA) and α-linolenic acid (ALA) are not metabolized to their long-chain products AA, EPA and DHA, the precursors of anti-inflammatory molecules, LXs, resolvins and protectins that could prevent NAFLD. This suggests that an imbalance between proand anti-inflammatory bioactive lipids contribute to NAFLD. Hence, it is proposed that plasma and tissue levels of AA, EPA, DHA and LXs, resolvins and protectins could be used as predictors and prognostic biomarkers of NAFLD. It is suggested that the synthesis and use of more stable analogues of LXs, resolvins and protectins need to be explored in the prevention and management of NAFLD.
作者 Undurti N Das
出处 《World Journal of Diabetes》 SCIE CAS 2011年第11期176-188,共13页 世界糖尿病杂志(英文版)(电子版)
基金 Supported by Ramalingaswami Fellowship of the Department of Biotechnology, India a grant from the Defense Research and Development Organisation, New Delhi, India
关键词 PROSTAGLANDINS Lipids Arachidonic ACID Eicosapentaenoic ACID Non-alcoholic fatty liver disease Docosahexaenoic ACID LIPOXINS RESOLVINS Protectins Cytokines Free radicals HYPERLIPIDEMIA Prostaglandins Lipids Arachidonic acid Eicosapentaenoic acid Non-alcoholic fatty liver disease Docosahexaenoic acid Lipoxins Resolvins Protectins Cytokines Free radicals Hyperlipidemia
  • 相关文献

参考文献119

  • 1Arnold C,Konkel A,Fischer R,Schunck WH.Cytochrome P450-dependent metabolism of omega-6 and omega-3 long- chain polyunsaturated fatty acids. Pharmacol Rep . 2010
  • 2Clark JM,Diehl AM.Hepatic steatosis and type 2 diabetes mellitus. Current Diabetes Reports . 2002
  • 3Sahoo S,Hart J.Histopathological features of L-asparagi- nase-induced liver disease. Seminars in Liver Disease . 2003
  • 4Sax HC,Bower RH.Hepatic complications of total paren- teral nutrition. Journal of Parenteral and Enteral Nutrition . 1988
  • 5Benjamin DR.Hepatobiliary dysfunction in infants and children associated with long-term total parenteral nutrition. A clinico-pathologic study. American Journal of Clinical Pathology . 1981
  • 6Van Aerde JE,Duerksen DR,Gramlich L,Meddings JB,Chan G,Thomson AB,Clandinin MT.Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cho- lestasis in newborn piglets. Pediatric Research . 1999
  • 7Chen WJ,Yeh SL.Effects of fi sh oil in parenteral nutrition. Nutrition . 2003
  • 8Sekiya M,Yahagi N,Matsuzaka T,Najima Y,Nakakuki M,Nagai R,Ishibashi S,Osuga J,Yamada N,Shimano H.Poly- unsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology . 2003
  • 9Das UN.Metabolic syndrome pathophysiology: the role of essential fatty acids. . 2010
  • 10Diehl AM,Li ZP,Lin HZ,Yang SQ.Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut . 2005

共引文献18

同被引文献4

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部